CD133 as Biomarker and Therapeutic Target in Gynecologic Malignancies

Fiore, Riccardo Di; Suleiman, Sherif; Calleja‐Agius, Jean

doi:10.1007/16833_2023_139

Cited by 2 publications

(1 citation statement)

References 240 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gynecological cancers (GCs), encompassingbreast, cervical, ovarian, and uterine cancers, pose a substantial global health burden, with malignancies playing a prominent role [ 1 ]. These cancers affecting women’s health are a matter of great concern, as they have a significant impact on the lives of those affected [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

The emerging roles of long non-coding RNA (lncRNA) H19 in gynecologic cancers

Ghasemian,

Zehtabi,

Dari

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Long non-coding RNA (lncRNA) H19 has gained significant recognition as a pivotal contributor to the initiation and advancement of gynecologic cancers, encompassing ovarian, endometrial, cervical, and breast cancers. H19 exhibits a complex array of mechanisms, demonstrating dualistic effects on tumorigenesis as it can function as both an oncogene and a tumor suppressor, contingent upon the specific context and type of cancer being investigated. In ovarian cancer, H19 promotes tumor growth, metastasis, and chemoresistance through modulation of key signaling pathways and interaction with microRNAs. Conversely, in endometrial cancer, H19 acts as a tumor suppressor by inhibiting proliferation, inducing apoptosis, and regulating epithelial-mesenchymal transition. Additionally, H19 has been implicated in cervical and breast cancers, where it influences cell proliferation, invasion, and immune evasion. Moreover, H19 has potential as a diagnostic and prognostic biomarker for gynecologic cancers, with its expression levels correlating with clinical parameters and patient outcomes. Understanding the functional roles of H19 in gynecologic cancers is crucial for the development of targeted therapeutic strategies and personalized treatment approaches. Further investigation into the intricate molecular mechanisms underlying H19’s involvement in gynecologic malignancies is warranted to fully unravel its therapeutic potential and clinical implications. This review aims to elucidate the functional roles of H19 in various gynecologic malignancies.

show abstract

Section: Introductionmentioning

confidence: 99%